Trump's Drug Price Promise: Why New Legislation Might Hike Costs Instead

Trump's promise to tackle prescription drug prices might backfire. The new legislation, while aiming to bring prices down, could end up increasing them.

The Promise and the Plan

President Trump, alongside a Republican Congress, has made bold promises about reducing prescription drug costs. But the Consolidated Appropriations Act of 2026 might actually undercut these efforts. The act aims to restructure Pharmacy Benefit Managers (PBMs), shifting them from tough negotiators to mere administrators, which could weaken their power to drive down prices.

For years, PBMs have been the middlemen in this space, using their use to negotiate better prices from drug manufacturers. By threatening to withhold formulary placement, PBMs compel manufacturers to offer competitive prices. Yet, the new legislation proposes to delink PBM compensation from these rebates. This means PBMs might lose their financial incentive to bargain aggressively, transforming cost negotiation into just another administrative task. When bargaining effort isn't profitable, the drive for aggressive price cuts fades.

Dissecting the Opposition

There's a reason some see this change as necessary. PBMs, though effective, are often criticized for their opaque processes. Figures like Mark Cuban have even labeled the way PBMs operate as absurd. For years, manufacturers and independent pharmacies have pointed fingers at PBMs, arguing these middlemen complicate the drug pricing system and often drive up costs. Attacking PBMs is popular because it seems like an easy fix.

But let's ask ourselves, is targeting PBMs really the solution? Weakening these middlemen might shift power back into the hands of drug manufacturers, the very entities setting the high prices. When you weaken the bargaining side, the scales tip. Prices may not go down, instead, they might climb higher.

The Real Cost

So, who stands to lose the most? Seniors on Medicare and smaller employers face the brunt of these changes. The proposed legislation could especially impact those without the use to negotiate lower prices themselves. And while broadening the inclusion of pharmacies under standardized terms feels inclusive, it often ends up shifting costs rather than reducing them. More options don’t always mean lower prices.

PBMs have been instrumental in funneling business to lower-cost pharmacies, maintaining their negotiating use. The new act, however, would dismantle this ability, potentially making the system less efficient. In Buenos Aires, stablecoins aren't speculation. They're survival. Here, the same could be said for effective negotiation in healthcare.

Verdict: What's Next?

Here's the thing: the market doesn't need more regulation, it needs smarter competition. Strengthening the power of PBMs might seem counterintuitive, but they've proven capable of driving prices down through tough negotiations. Instead of weakening their autonomy, Congress should focus on enhancing competitive pressure within the drug market.

Latin America doesn’t need crypto missionaries. It needs better rails. Likewise, the U.S. doesn’t need more middlemen. It needs more effective ones. If Congress continues down this path, the very people these reforms aim to protect might find themselves paying more. And that's a cost no one wants to bear.